Gilead Sciences Is Now More Attractive After Showing Superior Results Of Its Newest HIV Drug

Gilead's stock is extremely undervalued, and it still has high growth prospects due to new revolutionary drugs in its pipeline and a possible big acquisition. The average target price of the top analysts is at $84.17, an upside of 24.6%.